Halozyme Therapeutics, Inc. (NASDAQ:HALO) Holdings Raised by Mizuho Markets Americas LLC

Mizuho Markets Americas LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 10.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 446,661 shares of the biopharmaceutical company's stock after buying an additional 43,998 shares during the quarter. Mizuho Markets Americas LLC owned approximately 0.34% of Halozyme Therapeutics worth $16,509,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Principal Securities Inc. purchased a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at about $34,000. First Horizon Advisors Inc. lifted its position in Halozyme Therapeutics by 24.5% during the fourth quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company's stock valued at $55,000 after acquiring an additional 293 shares during the last quarter. Parkside Financial Bank & Trust acquired a new stake in Halozyme Therapeutics in the fourth quarter valued at approximately $64,000. Headlands Technologies LLC grew its holdings in Halozyme Therapeutics by 1,068.2% in the fourth quarter. Headlands Technologies LLC now owns 1,764 shares of the biopharmaceutical company's stock worth $65,000 after purchasing an additional 1,613 shares during the last quarter. Finally, Quadrant Capital Group LLC grew its holdings in Halozyme Therapeutics by 22.4% in the fourth quarter. Quadrant Capital Group LLC now owns 3,414 shares of the biopharmaceutical company's stock worth $126,000 after purchasing an additional 624 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO traded down $0.68 during mid-day trading on Friday, hitting $44.71. The company's stock had a trading volume of 1,102,299 shares, compared to its average volume of 989,383. The business's fifty day moving average is $40.53 and its two-hundred day moving average is $38.55. The stock has a market cap of $5.69 billion, a price-to-earnings ratio of 18.48, a PEG ratio of 0.50 and a beta of 1.26. The company has a debt-to-equity ratio of 8.44, a current ratio of 6.64 and a quick ratio of 5.36. Halozyme Therapeutics, Inc. has a 1 year low of $31.86 and a 1 year high of $46.16.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts' consensus estimates of $0.77 by ($0.02). The company had revenue of $230.04 million during the quarter, compared to analysts' expectations of $235.25 million. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. Analysts anticipate that Halozyme Therapeutics, Inc. will post 3.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

HALO has been the subject of a number of recent analyst reports. JMP Securities lowered their price objective on Halozyme Therapeutics from $72.00 to $71.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 8th. HC Wainwright restated a "buy" rating and set a $50.00 price objective on shares of Halozyme Therapeutics in a report on Tuesday, May 7th. StockNews.com upgraded shares of Halozyme Therapeutics from a "hold" rating to a "buy" rating in a research note on Friday, February 23rd. TD Cowen started coverage on shares of Halozyme Therapeutics in a research note on Thursday, February 29th. They set an "outperform" rating and a $54.00 price target on the stock. Finally, Benchmark reiterated a "buy" rating and set a $50.00 price objective on shares of Halozyme Therapeutics in a research note on Tuesday, April 16th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $53.14.

Insider Activity

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the company's stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $41.64, for a total value of $416,400.00. Following the completion of the transaction, the senior vice president now owns 156,558 shares in the company, valued at $6,519,075.12. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold a total of 30,000 shares of company stock valued at $1,196,800 in the last three months. 2.40% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.